When the article “The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia” (Donald C. Goff, M.D., et al. [doi:
https://doi.org/10.1176/appi.ajp.2017.16091016]) was published online May 5, it did not include all of the disclosures that the authors provided. Here is how the disclosure section should read:
Dr. Goff has received research support from Avanir Pharmaceuticals, NIMH, and the Stanley Medical Research Institute. Dr. Falkai has received speaking fees from Janssen, Lilly, Otsuka, and Servier and has received honoraria for serving on advisory boards for Janssen, Otsuka, and Servier. Dr. Fleischhacker has received research support from Boehringer-Ingelheim, Janssen, Lundbeck, and Otsuka; he has received honoraria for serving as a consultant to and/or on advisory boards for Allergan, Dainippon Sumitomo, Gedeon Richter, Janssen, Lundbeck, Otsuka, Takeda, and Teva; and he has received speaker’s fees and travel support from AOP Orphan, Dainippon Sumitomo, Gedeon Richter, Janssen, Lundbeck, Pfizer, Otsuka, and Teva. Dr. Girgis receives research support from Allergan, BioAdvantex, Genentech, and Otsuka. Dr. Kahn has received consulting fees from Alkermes, Forrest, Forum, Gedeon-Richter, Janssen-Cilag, Minerva Neurosciences, and Sunovion and speaker’s fees from Janssen-Cilag and Lilly. Dr. Uchida has received grants from Astellas Pharmaceutical, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Meiji-Seika Pharmaceutical, Mochida Pharmaceutical, Novartis, Otsuka Pharmaceutical, and Shionogi; speaker’s honoraria from Dainippon-Sumitomo Pharma, Eli Lilly, Janssen Pharmaceutical, Meiji-Seika Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Shionogi, and Yoshitomi Yakuhin; and advisory panel payments from Dainippon-Sumitomo Pharma. Dr. Lieberman has received support administered through his institution in the form of funding or medication supplies for investigator-initiated research from Denovo, Genentech, Pfizer, Sunovion, and Taisho and for company sponsored phase II, III, and IV studies from Alkermes and Allergan, and is a consultant to or member of the advisory board of Intracellular Therapies, Lilly, Pierre Fabre, and Psychogenics. He neither accepts nor receives any personal financial remuneration for consulting, speaking, or research activities from any pharmaceutical, biotechnology, or medical device company. He has received honoraria for serving on an advisory board for Clintara, a clinical research organization, and holds a patent from Repligen that yields no royalties. Dr. Zhao reports no financial relationships with commercial interests.
This information has been updated for the article’s appearance in the September 2017 issue of The American Journal of Psychiatry and the online edition posted as part of that issue.
